RS50269B - NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I β-MIMETIKA - Google Patents

NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I β-MIMETIKA

Info

Publication number
RS50269B
RS50269B YU71901A YUP71901A RS50269B RS 50269 B RS50269 B RS 50269B YU 71901 A YU71901 A YU 71901A YU P71901 A YUP71901 A YU P71901A RS 50269 B RS50269 B RS 50269B
Authority
RS
Serbia
Prior art keywords
pharmaceutical preparation
preparation
salmeterol
acid
tiotropium bromide
Prior art date
Application number
YU71901A
Other languages
English (en)
Inventor
Karl-Heinz Bozung
Michel Pairet
Richard Reichl
Alexander Walland
Original Assignee
Boehringer Ingelheim Pharma Gmbh. & Co.Kg.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh. & Co.Kg., filed Critical Boehringer Ingelheim Pharma Gmbh. & Co.Kg.,
Priority to MEP-366/08A priority Critical patent/MEP36608A/xx
Publication of YU71901A publication Critical patent/YU71901A/sh
Publication of RS50269B publication Critical patent/RS50269B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Farmaceutski preparat, koji sadrži antiholinergik tiotropijum bromid, sa produženim dejstvom i β-mimetik salmeterol, sa produženim dejstvom, opciono u obliku svojih racemata, enantiomera i smeša, i opciono u obliku svojih farmakološki prihvatljivih adicionih soli sa kiselinom. Prijava sadrži još 8 patentnih zahteva.

Description

OPIS PRONALASKA
Ovaj pronalazak se odnosi na nove vrste lekovitih kompozicija na bazi tiotropijum bromida i salmeterola i na njihovu primenu u terapiji oboljenja disajnih puteva.
Stanje tehnike
Na osnovu stanja tehnike poznato je da se p-mimetici kao i antiholinergici uspešno mogu koristiti kao bronhijalni spazmolitici za lečenje opstruktivnih oboljenja disajnih puteva, kao npr. astme. Supstance sa p-simpatomimetskim dejstvom, kao npr. takođe, na osnovu stanja tehnike, poznata delotvorna supstanca formoterol, mogu prilikom primene kod ljudi ipak da budu skopčane sa neželjenim dejstvima.
Kao glavni simptomi mogu da se jave opšta uznemirenost, razdraženost, pospanost, strah, treptanje prstiju, napadi znojenja i bolovi glave. Pritom, inhalativna primena ne isključuje ove sporedne simptome, mada su ona uglavnom ipak nešto manja nego kod peroralne ili parenteralne primene.
Sporedni efekti p-simpatomimetika pri primeni kao sredstava za astmu, zasnivaju
se pre svega na više ili manje izraženim pl-stimulišućim dejstvima na srcu. Oni izazivaju tahikardiju, lupanje srca, tegobe nalik na anginu pektoris kao i aritmije.
[P.T. Ammon (izd.), Arzneimittelnebemvirkungen und - wechselwirkungen, Wis-senschaftliche Verlagsgesellschaft, Stutgart 1986, str. 584].
Opis pronalaska
Iznenada je otkriveno da se gore navedeni sporedni simptomi mogu znatno umanjiti kombinacijom titropijum bromida i salmeterola.
Pritom je potpuno neočekivano takođe utvrđeno, da se bronhospazmolitičko delovanje antiholinergetika titropijum bromida sa produženim dejstvom i p-mimetika salmeterola sa produženim dejstvom, pojačava više nego što je njihovo zbirno delovanje.
Sa kombinacijom delotvornih supstanci, na osnovu pronalaska, može se dakle očekivati znatno poboljšano delovanje, u odnosu na osnovu stanja tehnike poznatih pojedinačnih supstanci i kombinacija, kako kod COPD tako i kod astme. Salmeterolom, u datom slučaju, može biti upotrebljen u obliku racemata, enantiomera, dijastereomera i smeša, kao i, u datom slučaju, farmakološki neškodljivih adicionih soli sa kiselinom.
Kao što je prethodno pomenuto, salmeterol može da se prevede i upotrebi u oblik svojih fiziološki i farmakološki podnošljivih soli. Za pripremanje adicionih soli sa kiselinom u obzir dolaze, na primer, sona kiselina, bromovodonična kiselina, sumporna kiselina, fosforna kiselina, metansulfonska kiselina, sirćetna kiselina, fumarna kiselina, ćilibarna kiselina, mlečna kiselina, limunska kiselina, vinska kiselina ili maleinska kiselina. Osim toga mogu da se upotrebe smeše pomenutih kiselina.
Na osnovu pronalaska, salmeterol, u datom slučaju, je u obliku svojih enantiomera, od kojih najveću prednost ima (R)-enantiomer, kao i, u datom slučaju, njegove farmakološki neškodljive soli.
Prema pronalasku, kompozicije sa delotvornim komponentama, prvenstveno se pripremaju u obliku dozirnog aerosola, ali je takođe moguć i bilo koji drugi oblik za parenteralno ili oralno davanje. Pritom, primena dozirnih aerosolova predstavlja oblik primene koji ima prednost, naročito u terapiji opstruktivnih plućnih oboljenja ili u lečenju astme.
Pored primene u dozirnim aerosolovima, koji rade na bazi potisnih gasova, mogu kombinacije delotvornih supstanci, na osnovu pronalaska, da se primene pomoću tzv. raspršivača za stvaranje magle (nebulajzera), pomoću kojih se rastvori farmakološki aktivnih supstanci pod povišenim pritiskom tako raspršuju, da dolazi do stvaranja magle čestica koje se inhaliraju. Prednost takvih raspršivača za stvaranje magle je u tome što se unošenje potisnih gasova može potpuno izbeći.
Obično su određeni lekovi za inhaliranje rastvoreni u vodenom ili etanolskom rastvoru, pri čemu su, već prema karakteristikama rastvora delotvorne supstance, pogodne takođe i smeše rastvarača, sa vodom i etanolom.
Vrste takvih raspršivača za stvaranje magle su, na primer, opisane u PCT-patentnoj prijavi WO 91/14468 i u internacionalnoj patentnoj prijavi pod oznakom predmeta PCT/EP96/04351, koje se ovim u celini uzimaju u obzir. Kod tamo opisanih ras-pršivača za stvaranje magle, koji su takođe poznati pod oznakom Respimat<®>, raspr-šuju se, kroz male dizne, određene zapremine rastvora koji sadrže delotvornu supstancu, pod dejstvom povišenog pritiska, tako da se aerosol koji se inhalira stvara sa najpovoljnijom veličinom čestica između 1 i 10, prvenstveno između 2 i 5 mikrometara.
Kao rastvarači za lekovite preparate pogodne su, između ostalog, smeše, koje na primer sadrže etanol kao rastvarač.
Dalji sastojci rastvarača su pored vode, u datom slučaju, drugi kosolventi, a lekoviti preparat može takođe da sadrži, supstance koje daju ukus kao i druga farmaceut-ska pomoćna sredstva. Primeri kosolvenata su oni koji sadrže hidroksilne grupe ili druge polarne grupe, na primer alkohole, naročito izopropilalkohol, glikole, naro-čito propilenglikol, polietilenglikol, polipropilenglikol, glikoletar, glicerol, polioksi-etilenalkohole i polioksietilen estre masnih kiselina. Kosolventi su pogodni za to da povećaju rastvorljivost pomoćnih supstanci a, u datom slučaju, i delotvornih supstanci.
Druga farmakološka pomoćna sredstva, kao na primer sredstva za konzerviranje, naročito benzalkonijumhlorid, mogu da budu dodata. Povoljna količina sredstva za konzerviranje, naročito benzalkonijumhlorida, nalazi se između 8 i 12 mg/100 ml rastvora.
Da bi se izbegle anomalije pri raspršivanju mogu se kombinaciji delotvornih supstanci dodati sredstva za kompleksiranje. Pogodna sredstva za kompleksiranje su ona koja su farmakološki podnošljiva, naročito ona koja su već dozvoljena za upotrebu u lekovima. Naročito su pogodni EDTA, nitrilotrisirćetna kiselina, limunska kiselina i askorbinska kiselina, kao i njihove soli. Naročito je pogodna dinatrijumova so etilendiamintetrasirćetne kiseline.
Udeo rastvorene kombinacije delotvornih supstanci u gotovom lekovitom prepa-ratu iznosi između 0,001 i 5%, prvenstveno između 0,005 i 3%, a naročito 0,01 do 2%. Maksimalna koncentracija lekovite supstance zavisi od rastvorljivosti u rastvaraču i od potrebnog doziranja radi postizanja željenog terapeutskog dejstva.
Sledeći oblici preparata navode se kao primeri formulacija:
Pored toga, kombinacije delotvornih supstanci, prema pronalasku, mogu takođe da se inhaliraju i u obliku praha. Pripremanje takvih oblika preparata poznato je na osnovu stanja tehnike. Oni sadrže pored kombinacije delotvornih supstanci koja odgovara ovom pronalasku i farmakološki neškodljive nosače ili pomoćna sredstva, kao npr. mikrokristalnu laktozu. Doza predviđena za inhaliranje može da bude u napunjenim kapsulama, i da na primer ima sledeći sadržaj:
Eksperimentalni rezultati
Bronhospazmolitičko i kardiovaskularno delovanje tiotropijumbromida, formoterolfumarata kao i njihovih kombinacija, posle inhalativne primene vodenog rastvora pomoću Respimat<®>, na narkotiziranim psima.
Materijal i postupak
18 pasa mešovite rase, telesne mase od 27 do 32 kg. Držani u pojedinačnim, odn. skupnim boksovima, peletirana standardna hrana, poslednje hranjenje ca. 15 sati pre ogleda, pijaća voda ad libitum.
Posle prethodnog tretmana sa 2 mg/kg morfinhidrohlorida i.m. polako je injicira-no intravenski 30 mg/kg pentobarbital-natrijuma (Nembutal<®>). Životinje su relaksirane sa 1,0 mg/kg i.v. suksametonijuma.
Životinjama je posle intubiranja, pomoću Servo-Ventilator-a 900 C (firma Siemens) omogućeno disanje uduvavanjem sobnog vazduha i kiseonika (4:1), frekvenca 15/min, udahnuta zapremina 6 - 8 lit./min. Za registrovanje mehanike disanja odre-đivan je protok disanja, pomoću cevi za dinamički pritisak (Fleisch Nr. 1), koja je postavljena neposredno pre orotrahejnog tubusa, registratora diferencijalnog pritiska i pojačivača DCB-4C. Jedan kateter je postavljen u traheju a drugi (balon-)kateter u deo pluća ezofagusa. Obadva su povezana sa registratorom i pojačivačem diferencijanog pritiska, radi određivanja transpulmonalnog pritiska. Računar za praćenje mehanike disanja (IFD-Miihlheim) davao je plućni otpor (R) na osnovu registrovanih vrednosti pritiska. Na osnovu toga je kompjuterski program VAS-1 LA (IFD-Miihlheim) određivao:
Registrovanje srčane frekvence vršeno je preko EKG (ekstremitetni odvod II) i kardiotahometra.
Posle perioda ekvilibrisanja od 30 min, izazivani su kratkotrajni bronhospazmi pomoću i.v. injekcije od 10 ug/kg acetilholinhlorida, koji su ponavljani 2 - 3 x u razmaku od ca. 10 min. Test-supstance, tiotropijumbromid, formoterolfumarat, kao i kombinacija obeju supstanci, davani su kao vodeni rastvori pomoću BINEB-ras-pršivača (Respimat<®>). Aplikacija kombinacije vršena je sa pojedinačnim komponentama u razmaku od ca. 1 min. Sa BINEB-sistemom mehanizam oslobađanja se odigravao na kraju faze izdisanja a raspršeni rastvor je u sledećoj fazi udisanja potiskivan pomoću pumpe za disanje u traheobronhijalno stablo.
Doziranja
Tabele 1 - 6 prikazuju, u toku 180 min, polazne vrednosti i vrednosti posle davanja supstanci. Na slikama 1 - 2 prikazana su procentualno, u toku 180 min, inhibiranja povećanih plućnih otpora izavanih pomoću ACh
Rezultati
Rezultati su prikazani ua tabelama kao i na slikama. 3 i 10 ug tiotropijumbromida, odn. formoterolfumarata znatno inhibiraju bronhijani otpor, srazmerno povećavan dozom intravenskim injiciranjem ACh. Maksimalno bronhospazmolitičko dejstvo formoterol-a FU brzo nastupa sa oba doziranja, a sa tiotropijum-om BR je odložena za. oko 60 min. Trajanje delovanja formoterol-a FU pre svega je pri manjim doziranjima srazmerno kratko, a ono sa tiotropijum BR, prema očekivanju, održava se do kraja opita (180 min).
Sa kombinacijom od 3 ug tiotropijum bromida + 3 ug formoterol-a FU, vrlo brzo se postiže izražena bronhospazmoliza od 90%, koja se do kraja opita skoro neprome-njeno održava. Zaštitno dejstvo kombinacije veoma značajno nadmašuje dejstvo pojedinačnih komponenti, ali takođe prevazilazi i zbir pojedinačnih efekata, 3 ug tiotropijim bromida i 3 ug formoterol-a FU. Ono prevazilazi efekat koji ima 10 ug tiotropijum bromida, odn. 10 ug formoterol fumarata (v. sliku 2).
Sam tiotropijum bromid nema bilo kakav uticaj na srčanu frekvencu, kako ni sa 3 ug tako ni sa 10 ug. Nasuprot tome, formoterol FU je povećava, srazmerno dozi, a pre svega pri visokim dozama, maksimalno za preko 90%. Čak i na kraju ogleda izmerene su još vrednosti od preko 80%. Sa kombinacijama 3 + 3 ug, a takođe i sa 10 + 10 u.g tiotropijum bromida i formoterol fumarata, frekvencni efekti su primetno oslabljeni i leže ispod 30%.
Procena
Sa kombinacijom antiholinergika sa (3-mimetikom, nasuprot pojedinačnim supstan-cama, utvrđeni su potpuno neočekivani rezultati:
1. brzo otpočinjanje dejstva
2. dugotrajno delovanje
a pre svega
3. bronhospazmolitičko dejstvo koje prevazilazi zbirna dejstva i
4. znatno manji porast frekvence, pre svega sa većom dozom formoterola.
. Sa kombinacionim preparatom može da se očekuje znatno poboljšanje terapeutskog delovanja, kako kod COPD tako i kod astme, povezano sa prednošću uma-njenih kardijalnih pratećih dej stava.
Slike
51.1 prikazuje uticaj 3 ug formoterol fumarata, 3 ug tiotropijum bromida, kao i kombinacije, 3ugtiotropijum bromida + 3 ug formoterol fumarata, na bronhijalni otpor narkotiziranih pasa, n = 6.
51.2 prikazuje uticaj 10 ug formoterol fumarata, 10 ug tiotropijum bromida, kao i kombinacije, 3 ug tiotropijum bromida + 3 ug formoterol fumarata, na bronhijalni otpor narkotiziranih pasa, n = 6.

Claims (9)

1) Farmaceutski preparat, koji sadrži antiholinergik tiotropijum bromid, sa produženim dejstvom i (3-mimetik salmeterol, sa produženim dejstvom, opđono u obliku svojih racemata, enantiomera i smeša, i opciono u obliku svojih farmakološki prihvatljivih adicionih soli sa kiselinom.
2) Farmaceutski preparat prema zahtevu 1, naznačen time, što je salmeterol prisutan u obliku njegovog R-enantiomera.
3) Farmaceutski preparat, prema jednom od zahteva 1 ili 2, naznačen time, što je salmeterol prisutan u obliku soli ksinafoata.
4) Farmaceutski preparat, prema jednom od zahteva 1 do 3, naznačen time, što je to farmaceutski preparat koje se primenjuje inhalativno.
5) Farmaceutski preparat, prema jednom od zahteva 1 do 4, dalje sadrži farmakološki prihvatljive nosače ili pomoćne supstance.
6) Farmaceutski preparat, prema zahtevu 4 ili 5, naznačen time, što je prah.
7) Farmaceutski preparat, prema zahtevu 6, naznačen time, što sadrži laktozu kao farmakološki prihvatljiv nosač ili pomoćnu supstancu.
8) Upotreba preparate, prema jednom od zahteva 1 do 7, za pripremanje leka za lečenje oboljenja disajnih puteva.
9) Upotreba, prema zahtevu 8, za pripremanje leka za lečenje astme ili COPD.
YU71901A 1999-05-12 2000-05-03 NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I β-MIMETIKA RS50269B (sr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-366/08A MEP36608A (en) 1999-05-12 2000-05-03 Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19921693A DE19921693A1 (de) 1999-05-12 1999-05-12 Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika

Publications (2)

Publication Number Publication Date
YU71901A YU71901A (sh) 2005-07-19
RS50269B true RS50269B (sr) 2009-07-15

Family

ID=7907709

Family Applications (2)

Application Number Title Priority Date Filing Date
RSP-2009/0083A RS20090083A (sr) 1999-05-12 2000-05-03 Nove vrste kompozicija na bazi jedinjenja koja deluju antiholinergijski i beta-mimetika
YU71901A RS50269B (sr) 1999-05-12 2000-05-03 NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I β-MIMETIKA

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RSP-2009/0083A RS20090083A (sr) 1999-05-12 2000-05-03 Nove vrste kompozicija na bazi jedinjenja koja deluju antiholinergijski i beta-mimetika

Country Status (41)

Country Link
US (3) US6455524B1 (sr)
EP (7) EP1570861A3 (sr)
JP (5) JP4612956B2 (sr)
KR (2) KR100841909B1 (sr)
CN (2) CN1839833A (sr)
AR (1) AR023972A1 (sr)
AT (1) ATE245976T1 (sr)
AU (1) AU775588B2 (sr)
BG (1) BG65189B1 (sr)
BR (1) BR0010498A (sr)
CA (1) CA2368583C (sr)
CO (1) CO5140068A1 (sr)
CZ (1) CZ302328B6 (sr)
DE (2) DE19921693A1 (sr)
DK (1) DK1178832T3 (sr)
EA (1) EA004657B1 (sr)
EE (4) EE05677B1 (sr)
ES (1) ES2203470T3 (sr)
HK (1) HK1043064B (sr)
HR (1) HRP20010828A2 (sr)
HU (1) HUP0201103A3 (sr)
IL (3) IL146119A0 (sr)
ME (1) MEP36608A (sr)
MX (1) MXPA01011400A (sr)
MY (2) MY129512A (sr)
NO (2) NO328423B1 (sr)
NZ (1) NZ515596A (sr)
PE (1) PE20010133A1 (sr)
PL (2) PL206146B1 (sr)
PT (1) PT1178832E (sr)
RS (2) RS20090083A (sr)
SA (1) SA00210064B1 (sr)
SG (4) SG175465A1 (sr)
SI (1) SI1178832T1 (sr)
SK (1) SK287072B6 (sr)
TR (2) TR200103233T2 (sr)
TW (2) TWI272106B (sr)
UA (1) UA74547C2 (sr)
UY (1) UY26139A1 (sr)
WO (1) WO2000069468A1 (sr)
ZA (1) ZA200108942B (sr)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215396A1 (en) * 1999-09-15 2003-11-20 Boehringer Ingelheim Pharma Kg Method for the production of propellant gas-free aerosols from aqueous medicament preparations
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AU2001294808A1 (en) * 2000-09-29 2002-04-08 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020111363A1 (en) * 2000-10-31 2002-08-15 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
DE10206505A1 (de) * 2002-02-16 2003-08-28 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
US20020193392A1 (en) * 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2002085296A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
DE10126924A1 (de) * 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003013633A1 (en) * 2001-08-09 2003-02-20 Glaxo Group Limited Inhalation device with a pharmaceutical composition
EP1429768B1 (de) * 2001-09-14 2016-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Neue arzneimittel zur inhalation
US6919325B2 (en) 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
DE10212264A1 (de) † 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
US7244415B2 (en) * 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
AU2003221531B2 (en) * 2002-04-04 2008-10-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulations suitable for inhalation
UA80123C2 (en) * 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
US20030225089A1 (en) * 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
DE10216427A1 (de) * 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittelkompositionen enthaltend heterocyclische Verbindungen und ein neues Anticholinergikum
US7084153B2 (en) * 2002-04-12 2006-08-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising steroids and a novel anticholinergic
US7417051B2 (en) * 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US20040048887A1 (en) * 2002-07-09 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
DE10230751A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
UA83813C2 (ru) * 2002-12-20 2008-08-26 Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089892A2 (en) 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
ATE435862T1 (de) * 2003-05-28 2009-07-15 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
DE602004005462T2 (de) * 2003-07-29 2007-07-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medikamente zur inhalation mit betamimetika und einem anticholinergikum
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
DE10345065A1 (de) 2003-09-26 2005-04-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
PL1713471T3 (pl) * 2004-02-06 2012-06-29 Meda Pharma Gmbh & Co Kg Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych
DK1718336T3 (da) * 2004-02-06 2008-10-20 Meda Pharma Gmbh & Co Kg Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
AU2005210085B2 (en) * 2004-02-06 2010-06-24 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD
US7507745B2 (en) 2004-02-20 2009-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins
US20060189524A1 (en) * 2004-02-20 2006-08-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and pegsunercept
JP2007523117A (ja) * 2004-02-20 2007-08-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬及びｐｅｇｓｕｎｅｒｃｅｐｔを基にした新規な医薬組成物
US20050186175A1 (en) * 2004-02-20 2005-08-25 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on benzilic acid esters and soluble TNF receptor fusion proteins
US7071224B2 (en) * 2004-03-11 2006-07-04 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
WO2005087763A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
TW200540154A (en) * 2004-06-10 2005-12-16 Theravance Inc Crystalline form of a substituted pyrrolidine compound
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023457A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
EP1879571A1 (de) * 2005-04-23 2008-01-23 Boehringer Ingelheim International GmbH Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
JP5227790B2 (ja) * 2005-05-02 2013-07-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規結晶性臭化チオトロピウム
RU2418796C2 (ru) * 2005-06-15 2011-05-20 Берингер Ингельхайм Интернациональ Гмбх Способ получения новых солей тиотропия
CA2617897A1 (en) * 2005-08-06 2007-02-15 Boehringer Ingelheim International Gmbh Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
WO2007071313A2 (en) 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
AU2007267523B2 (en) * 2006-05-26 2012-02-09 Dey, L.P. Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
NZ587561A (en) * 2008-02-26 2012-10-26 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
AU2010253770B9 (en) * 2009-05-29 2015-02-12 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
HRP20151317T1 (hr) 2011-06-10 2016-01-01 Chiesi Farmaceutici S.P.A. Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora
RU2606121C2 (ru) 2011-06-10 2017-01-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
TW201311649A (zh) * 2011-09-05 2013-03-16 Everlight Chem Ind Corp 用於太陽能電池電解液之化合物及其製法、含有該化合物之電解液及太陽能電池
KR102156441B1 (ko) 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
EP3345904B1 (en) 2012-12-06 2020-07-29 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3484879B1 (en) 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EA201990605A1 (ru) * 2016-10-14 2019-10-31 Распыляемые композиции тиотропия и формотерола
JP6963616B2 (ja) 2016-12-14 2021-11-10 ベイジン ショウバイ ファーマシューティカル カンパニー，リミティッド ４級アンモニウム塩構造を有する二官能性化合物
SG11201906632WA (en) 2017-01-31 2019-08-27 Alphinity Llc Bioprocess vessels with integrated pump
CN117679423A (zh) 2022-09-05 2024-03-12 立生医药(苏州)有限公司 预防或治疗呼吸系统疾病的吸入用药物组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613811D0 (en) 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
ATE92762T1 (de) * 1989-09-08 1993-08-15 Glaxo Group Ltd Medikamente.
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE4003270A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DK0617610T3 (da) * 1991-12-18 1997-10-06 Minnesota Mining & Mfg Suspensionsaerosolformuleringer.
EP0673240B1 (en) * 1992-12-09 1999-03-24 Boehringer Ingelheim Pharmaceuticals Inc. Stabilized medicinal aerosol solution formulations
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DE19528145A1 (de) * 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US6254882B1 (en) * 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
ATE283033T1 (de) * 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
DE19847970A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähige Wirkstoff-Formulierung
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika

Also Published As

Publication number Publication date
EP2266621A3 (de) 2013-01-23
PL199442B1 (pl) 2008-09-30
EP2266620A2 (de) 2010-12-29
CA2368583A1 (en) 2000-11-23
SG175465A1 (en) 2011-11-28
PT1178832E (pt) 2003-12-31
SG158731A1 (en) 2010-02-26
NO328423B1 (no) 2010-02-15
IL146119A (en) 2006-08-01
PE20010133A1 (es) 2001-03-02
HK1043064B (zh) 2006-08-18
ZA200108942B (en) 2002-08-26
SI1178832T1 (sl) 2003-12-31
CN1250290C (zh) 2006-04-12
PL352131A1 (en) 2003-07-28
JP2002544239A (ja) 2002-12-24
YU71901A (sh) 2005-07-19
EE201000018A (et) 2010-04-15
DK1178832T3 (da) 2003-11-03
JP2006188534A (ja) 2006-07-20
TR200103233T2 (tr) 2002-04-22
NO20015359D0 (no) 2001-11-02
TWI272106B (en) 2007-02-01
US6455524B1 (en) 2002-09-24
CO5140068A1 (es) 2002-03-22
EE05677B1 (et) 2013-10-15
HK1043064A1 (en) 2002-09-06
BG106095A (bg) 2002-06-28
MY129512A (en) 2007-04-30
DE50003116D1 (de) 2003-09-04
UY26139A1 (es) 2000-12-29
EE200100594A (et) 2003-02-17
MXPA01011400A (es) 2002-06-04
US6433027B1 (en) 2002-08-13
EA004657B1 (ru) 2004-06-24
EP2266620A3 (de) 2012-04-18
ES2203470T3 (es) 2004-04-16
MY134222A (en) 2007-11-30
HRP20010828A2 (en) 2003-02-28
ATE245976T1 (de) 2003-08-15
JP4612956B2 (ja) 2011-01-12
SA00210064B1 (ar) 2006-08-12
EP2269647A3 (de) 2012-04-18
EE05193B1 (et) 2009-08-17
HUP0201103A2 (hu) 2002-09-28
AU775588B2 (en) 2004-08-05
KR100841909B1 (ko) 2008-06-30
AR023972A1 (es) 2002-09-04
BG65189B1 (bg) 2007-06-29
SG179293A1 (en) 2012-04-27
SK287072B6 (sk) 2009-11-05
NO20093464L (no) 2001-11-02
IL172695A (en) 2011-07-31
CA2368583C (en) 2010-01-05
EE201000020A (et) 2010-04-15
IL146119A0 (en) 2002-07-25
KR100962059B1 (ko) 2010-06-10
EP2266621A2 (de) 2010-12-29
RS20090083A (sr) 2009-07-15
MEP36608A (en) 2011-02-10
NZ515596A (en) 2003-10-31
EP1178832B1 (de) 2003-07-30
KR20070050507A (ko) 2007-05-15
NO20015359L (no) 2001-11-02
BR0010498A (pt) 2002-02-26
HUP0201103A3 (en) 2008-10-28
AU4754500A (en) 2000-12-05
CN1839833A (zh) 2006-10-04
CN1350465A (zh) 2002-05-22
KR20020001876A (ko) 2002-01-09
UA74547C2 (en) 2006-01-16
EP2269648A2 (de) 2011-01-05
HRP20010828B1 (sr) 2013-01-31
SG178626A1 (en) 2012-03-29
EP1570861A2 (de) 2005-09-07
JP2011021038A (ja) 2011-02-03
EP2269647A2 (de) 2011-01-05
EP1327452A3 (de) 2004-01-21
IL172695A0 (en) 2006-04-10
EP1178832A1 (de) 2002-02-13
DE19921693A1 (de) 2000-11-16
EA200101156A1 (ru) 2002-06-27
US20020115681A1 (en) 2002-08-22
EE201000019A (et) 2010-04-15
US6630466B2 (en) 2003-10-07
WO2000069468A1 (de) 2000-11-23
EP1570861A3 (de) 2010-12-29
JP2011021037A (ja) 2011-02-03
TW200505483A (en) 2005-02-16
PL206146B1 (pl) 2010-07-30
SK16372001A3 (sk) 2002-03-05
EP2269648A3 (de) 2012-04-18
CZ20014055A3 (cs) 2002-02-13
CZ302328B6 (cs) 2011-03-16
TR200901979T2 (tr) 2009-05-21
EP1327452A2 (de) 2003-07-16
JP2011021036A (ja) 2011-02-03

Similar Documents

Publication Publication Date Title
EP1178832B1 (de) Neuartige arzneimittelkompositionen auf der basis von tiotropiumbromid und salmeterol
US9446054B2 (en) Pharmaceutical products and composition comprising specific anticholinergic agents, β-2 agonists and corticosteroids
US20210368853A1 (en) Nicotine Aerosol Formulation
KR20140007929A (ko) 호흡기 환자의 수면의 질을 개선하는데 사용되는 아클리디늄
ME00489B (me) NOVA SINERGIČKA KOMBINACIJA KOJA UKLJUČUJE ROFLUMILAST l FERMOTEROL
US20090180969A1 (en) Pharmaceutical formulation comprising an anticholinergic drug
KR20050094810A (ko) 로플루미래스트와 ｒ,ｒ-포르모테롤을 포함하는 상승작용성조합물
TWI924704B (zh) 茚達特羅(indacaterol)之液體調配物
WO2021138386A1 (en) Propellant-free formulation for inhalation
JP2005047833A (ja) 医薬組成物